Prognostic impact of stathmin 1 expression in patients with lung adenocarcinoma

Shimizu, Kimihiro; Ohtaki, Yoichi; Altan, Bolag; Yokobori, Takehiko; Nagashima, Toshiteru; Arai, Motohiro; Mogi, Akira; Kuwano, Hiroyuki

doi:10.1016/j.jtcvs.2017.03.125

Cited by 12 publications

(16 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistently, accumulating evidence has suggested that elevated STMN1 expression is closely correlated not only with the development and progression of cancer, 10,11 but also with poor survival. 16,26,[57][58][59][60] The evidence from a meta-analysis by Rong et al 16 confirmed that the overexpression of STMN1 was positively associated with high tumor stage, poor differentiation, and lymph node invasion. 10 However, to date, the prognostic value of STMN1 expression in solid tumors has not been systematically assessed by meta-analysis.…”

Section: Discussionmentioning

confidence: 94%

Association of STMN1 with survival in solid tumors: A systematic review and meta-analysis

et al. 2019

View full text Add to dashboard Cite

Background: The prognostic value of Stathmin 1 (STMN1) in malignant solid tumors remains controversial. Thus, we conducted this meta-analysis to summarize the potential value of STMN1 as a biomarker for predicting overall survival in patients with solid tumor. Methods: We systematically searched eligible studies in PubMed, Web of Science, and EMBASE from the establishment date of these databases to September 2018. Hazard ratio (HR) and its 95% confidence interval (CI) was used to assess the association between STMN1 expression and overall survival. Results: A total of 25 studies with 4625 patients were included in this meta-analysis. Our combined results showed that high STMN1 expression was associated with poor overall survival in solid tumors (HR = 1.85, 95% CI 1.55, 2.21). In general, our subgroup and sensitivity analyses demonstrated that our combined results were stable and reliable. However, from the results of the subgroups we found that high STMN1 expression was not related to overall survival in colorectal cancer and endometrial cancer anymore, suggesting that much caution should be taken to interpret our combined result, and more studies with large sample sizes are required to further explore the prognostic value of STMN1 expression in the specific type of tumors, especially colorectal cancer and endometrial cancer. Conclusions: STMN1 could serve as a prognostic biomarker and could be developed as a valuable therapeutic target for patients with solid tumors. However, due to the limitations of the present meta-analysis, this conclusion should be taken with caution. Further studies adequately designed are required to confirm our findings.

show abstract

Section: Discussionmentioning

confidence: 94%

Association of STMN1 with survival in solid tumors: A systematic review and meta-analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Deparaffinization, rehydration, and antigen retrieval were performed by CC1 (prediluted; pH 8) antigen retrieval solution (reference 950-124; Ventana Medical Systems, Inc, Tucson, AZ), on a Ventana BenchMark-Ultra stainer (64 minutes at 100 C). Specimens were incubated with primary mouse anti-STMN1 antibody (OP18; dilution 1:200; Santa Cruz Biotechnology, Santa Cruz, CA; 32 minutes at 37 C) [6], then visualized with the OptiView DAB IHC and Amplification Kits (Ventana Medical Systems) for 12 minutes. The specimens were then counterstained with hematoxylin II and bluing reagent (Ventana Medical Systems) and placed on a coverslip.…”

Section: Ihc Stainingmentioning

confidence: 99%

“…STMN1 may thus be an attractive target for the diagnosis and treatment of malignant tumors [4,5]. We previously reported that STMN1 expression in lung adenocarcinoma (AD) and squamous cell carcinoma (SCC) was associated with vascular invasion, advanced tumor-node-metastasis stage, and shorter survival [6,7].…”

mentioning

confidence: 99%

“…Uribarri and colleagues [8] reported that STMN1 protein was overexpressed in small-cell lung cancer (SCLC) in bronchoalveolar lavage (BAL) and could help discriminate between non-small cell lung cancer (NSCLC) and SCLC. In our previous studies [6,7], we occasionally encountered poorly differentiated NSCLC samples with extremely high STMN1 expression (using immunohistochemical [IHC] staining), which were difficult to distinguish pathologically from high-grade lung neuroendocrine tumor (HGNET), especially large-cell neuroendocrine carcinoma (LCNEC). From the findings of Uribarri and colleagues [8] and our experience, we hypothesized that STMN1 protein expression may be used for differential diagnosis between NSCLC and HGNET.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Stathmin-1 Is a Useful Diagnostic Marker for High-Grade Lung Neuroendocrine Tumors

Shimizu

Goto

Kawabata‐Iwakawa

et al. 2019

The Annals of Thoracic Surgery

Self Cite

View full text Add to dashboard Cite

Background. Stathmin-1 regulates microtubule dynamics and is associated with malignant phenotypes in non-small cell lung cancer (NSCLC). This study evaluated its diagnostic value for differentiating between NSCLC and high-grade lung neuroendocrine tumor (HGNET).Methods. Stathmin-1 protein expression was assessed by immunohistochemistry in 414 NSCLC (305 adenocarcinoma [AD], 102 squamous cell carcinoma [SCC], 7 largecell carcinoma), 5 typical carcinoid (low-grade lung neuroendocrine tumor), and 34 HGNET (17 small-cell carcinoma [SCLC] and 17 large-cell neuroendocrine carcinoma [LCNEC]) surgical specimens and 57 NSCLC (29 AD and 28 SCC) and 42 HGNET (17 LCNEC and 25 SCLC) biopsy specimens. We also analyzed stathmin-1 mRNA levels in 81 NSCLCs and 26 HGNETs with the use of reverse transcription-polymerase chain reaction.Results. Among NSCLC samples, we saw high stathmin-1 protein expression in only three ADs, one SCC, and one large-cell carcinoma surgical samples, all five of which showed neuroendocrine characteristics in pathologic re-review; and low or intermediate expression in all five typical carcinoid surgical samples and all 57 NSCLC biopsy samples. In contrast, all HGNET surgical (n [ 34) and biopsy (n [ 42) samples showed high stathmin-1 expression. In reverse transcriptionpolymerase chain reaction, stathmin-1 expression was significantly higher in HGNET tissues than in NSCLC tissues (p < 0.001).Conclusions. Stathmin-1 expression can help in differentiating NSCLC from HGNET.

show abstract

“…It was originally identified in leukemia, where OP18 was found to be highly expressed [34,35]. In the past, OP18 has been studied most extensively in breast, gastric and lung cancer due to the high prevalence of these diseases [36][37][38][39][40][41][42].…”

Section: Functional Insights Into the Biological Role Of Op18 And Itsmentioning

confidence: 99%

Oncoprotein 18 is necessary for malignant cell proliferation in bladder cancer cells and serves as a G3-specific non-invasive diagnostic marker candidate in urinary RNA

Hanke

Dubois

Kausch³

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

Background Urine-based diagnostics indicated involvement of oncoprotein 18 (OP18) in bladder cancer. In cell culture models we investigated the role of OP18 for malignant cell growth. Methods We analyzed 113 urine samples and investigated two human BCa cell lines as a dual model: RT-4 and ECV-304, which represented differentiated (G1) and poorly differentiated (G3) BCa. We designed specific siRNA for down-regulation of OP18 in both cell lines. Phenotypes were characterized by cell viability, proliferation, and expression of apoptosisrelated genes. Besides, sensitivity to cisplatin treatment was evaluated. Results Analysis of urine samples from patients with urothelial BCa revealed a significant correlation of the RNA-ratio OP18:uroplakin 1A with bladder cancer. High urinary ratios were mainly found in moderately to poorly differentiated tumors (grade G2-3) that were muscle invasive (stage T2-3), whereas samples from patients with more differentiated non-invasive BCa (G1) showed low OP18:UPK1A RNA ratios. Down-regulation of OP18 expression in ECV-304 shifted its phenotype towards G1 state. Further, OP18-directed siRNA induced apoptosis and increased chemo-sensitivity to cisplatin. Conclusions This study provides conclusive experimental evidence for the link between OP18-derived RNA as a diagnostic marker for molecular staging of BCa in non-invasive urine-based

show abstract

Prognostic impact of stathmin 1 expression in patients with lung adenocarcinoma

Abstract: Stathmin 1 expression was an independent prognostic factor for adenocarcinoma, even when restricted to patients with early-stage cancer.

Cited by 12 publications

References 20 publications

Association of STMN1 with survival in solid tumors: A systematic review and meta-analysis

Association of STMN1 with survival in solid tumors: A systematic review and meta-analysis

Stathmin-1 Is a Useful Diagnostic Marker for High-Grade Lung Neuroendocrine Tumors

Oncoprotein 18 is necessary for malignant cell proliferation in bladder cancer cells and serves as a G3-specific non-invasive diagnostic marker candidate in urinary RNA

Contact Info

Product

Resources

About